Security key
12529R107
C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC)
CUSIP: 12529R107
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 64,100,740
- Total 13F value
- $102,562,013
- Share change
- -278,696
- Put/Call ratio
- 0%
- SEC-reported price per share
- $1.60
- Number of holders
- 113
- Value change
- -$12,577,745
- Number of buys
- 64
- Number of sells
- 52
- Shares outstanding
- 110,144,928
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
113
Top holders
10
CCCC full security history
Ownership snapshot
Full 13F holder table
C4 Therapeutics, Inc. SEC filings
C4 Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CCCC - C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Soleus Capital Management...
Disclosed value leader
Soleus Capital Management...
Comparable rows
15/15
Latest evidence
31 Dec 2024
13F
Lead comparable stake: 6.3%
Showing 1-6 of 15 holder rows.
Quick read
Soleus Capital Management, L.P. leads the comparable SEC ownership view at 6.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Soleus Capital Management, L.P.'s linked filing trail.
Comparable ownership
Top 5
Soleus Capital Management, L.P.
6.3%
Lynx1 Capital Management LP
6.2%
WASATCH ADVISORS LP
5.5%
BlackRock, Inc.
5%
RA CAPITAL MANAGEMENT, L.P.
4.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Soleus Capital Management, L.P. |
13F
Company
|
6.3%
|
$25,124,191
6,978,942 shares
|
— | 31 Dec 2024 |
| Lynx1 Capital Management LP |
13F
Company
|
6.2%
|
$24,669,878
6,852,744 shares
|
— | 31 Dec 2024 |
| WASATCH ADVISORS LP |
13F
Company
|
5.5%
|
$21,861,364
6,072,601 shares
|
— | 31 Dec 2024 |
| BlackRock, Inc. |
13F
Company
|
5%
|
$20,011,863
5,558,851 shares
|
— | 31 Dec 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
4.4%
|
$17,560,800
4,878,000 shares
|
— | 31 Dec 2024 |
| ORBIMED ADVISORS LLC |
13F
Company
|
4%
|
$15,760,440
4,377,900 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
113
Shares
64,100,740
Rows available
113
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q1 2025 Across Filers
Q1 2025 holders
113
Q1 2025 holders
113
Holder diff
0
| Investor | Q1 2025 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q1 2025 value | Value change | Value Chg % |
|---|